TAOX
TAO シナジー
TAO Synergies Inc.
プレマーケットデータ（自動更新なし）20日平均DV $301,434?
Earnings 2026-12-0252W high -65.6%52W low +8.2%Market cap $11MAvg volume 89K
Company Overview
Clinical-stage biopharmaceutical company developing a bryostatin‑1 platform for Alzheimer’s and other neurodegenerative/cognitive diseases. Also pivoting to a digital-asset treasury strategy focused on acquiring and staking TAO cryptocurrency.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | -1.83 | $88,626 | -$874,980 |
| 2026 Q1 | 0.45 | $388,774 | -$2M |
| 2025 Q4 | -1.04 | $91,728 | -$2M |
| 2025 Q3 | -1.56 | $203,371 | -$1M |
| 2025 Q2 | -11.26 | $3,962 | -$749,072 |
| 2025 Q1 | 0.12 | $0 | -$2M |
|
